Mode
Text Size
Log in / Sign up
Phase 2 Completed N=24 Treatment

Effects of PRK 124 Lotion in Acne Rosacea

Acne Rosacea
Source: ClinicalTrials.gov NCT00580723 ↗
Enrolled (actual)
24
Serious AEs
0.0%
Results posted
Dec 2013
Primary outcomePrimary: Erythema Severity — 44.53 Erythema percent improvement

Summary

The purpose of this open-label study is to determine the tolerance and efficacy of twice-daily application of PRK 124 (Pyratine-6)(0.125%) moisturizing lotion for improving the signs and symptoms of mild to moderate facial rosacea.

Outcome Measures

OutcomeResultp-value
PRIMARY
Erythema Severity
44.53 —
PRIMARY
Inflammatory Lesion Count
89 —
PRIMARY
Telangiectasia Severity
27.88 —
SECONDARY
Skin Tolerance
— —
SECONDARY
Skin Photodamage
— —
SECONDARY
Transepidermal Water Loss (TEWL)
— —
SECONDARY
Cosmetic Acceptability
— —

Eligibility Criteria

Inclusion Criteria

  • be at least 21 years old
  • be in reasonably good health as defined by the study doctor
  • have routine laboratory tests to evaluate your blood cell count, and kidney and liver function
  • for females of child-bearing age, not be pregnant or nursing and have a negative urine pregnancy test (except if surgically sterile or at least 1 year menopausal)
  • for females, agree to use medically acceptable forms of birth control throughout the entire study (medically acceptable forms of birth control include oral contraceptive ["the pill"], implants such as Norplant®, injectable progesterone [Depo-provera®], diaphragm and spermicide or condoms and spermicide)
  • must have mild to moderate acne rosacea
  • be willing to refrain from using non-approved lotions, moisturizer, cleansers or lotions on affected facial areas during the treatment period
  • be capable of understanding and giving written, voluntary informed consent before study screening
  • be willing to consent to facial photographs at baseline and each follow-up visit to monitor treatment with the test product.

Exclusion Criteria

  • have a history or evidence of any chronic or reoccurring skin disease or disorder (e.g., psoriasis, eczema, etc.) affecting the face
  • have known or suspected hypersensitivity to study treatment or any of its ingredients
  • have used systemic retinoids within 6 months prior to study entry (e.g., acitretin, isotretinoin)
  • have received treatment with systemic corticosteroids (e.g. prednisone) or antibiotics within 1 month
  • have used topical treatment to the face with retinoids (e.g. tretinoin, adapalene), or antibiotics or corticosteroids, within 2 weeks prior to study entry
  • are unwilling to use a sunscreen with an SPF of 30 during the study
  • have participated in any clinical trial involving an investigational drug or cosmetic product or procedure within the past 30 days
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00580723). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search